Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Sousa Pinto, Bernardo
  • dc.contributor.author Antó i Boqué, Josep Maria
  • dc.contributor.author Bousquet, Jean
  • dc.date.accessioned 2023-10-09T06:26:40Z
  • dc.date.available 2023-10-09T06:26:40Z
  • dc.date.issued 2023
  • dc.description Data de publicació electrònica: 03-08-2023
  • dc.description.abstract Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Sousa-Pinto B, Louis R, Anto JM, Amaral R, Sá-Sousa A, Czarlewski W, et al. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study. Pulmonology. 2023 Aug 3:S2531-0437(23)00130-7. DOI: 10.1016/j.pulmoe.2023.07.004
  • dc.identifier.doi http://dx.doi.org/10.1016/j.pulmoe.2023.07.004
  • dc.identifier.issn 2531-0429
  • dc.identifier.uri http://hdl.handle.net/10230/58057
  • dc.language.iso eng
  • dc.publisher Elsevier
  • dc.relation.ispartof Pulmonology. 2023 Aug 3:S2531-0437(23)00130-7
  • dc.rights © 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
  • dc.subject.keyword Adherence
  • dc.subject.keyword Asthma
  • dc.subject.keyword Formoterol
  • dc.subject.keyword Inhaled corticosteroids
  • dc.subject.keyword Long-acting-β2 agonist
  • dc.title Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion